Literature DB >> 35545534

Is apoCIII-Lowering A Double-Edged Sword?

Xiangming Tang1, Huanjin Zhou2, Haizhao Yan1,3, Manabu Niimi1, Jianglin Fan1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35545534      PMCID： PMC9252641          DOI： 10.5551/jat.LE002

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.394


× No keyword cloud information.
  19 in total

Review 1.  The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?

Authors:  Laurens F Reeskamp; Tycho R Tromp; Erik S G Stroes
Journal:  Curr Opin Lipidol       Date:  2020-06       Impact factor: 4.776

2.  Apolipoprotein C-III: going back to the future for a lipid drug target.

Authors:  Murray W Huff; Robert A Hegele
Journal:  Circ Res       Date:  2013-05-24       Impact factor: 17.367

3.  Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.

Authors:  W V Brown; M L Baginsky
Journal:  Biochem Biophys Res Commun       Date:  1972-01-31       Impact factor: 3.575

Review 4.  Apolipoprotein CIII is a new player in diabetes.

Authors:  Lisa Juntti-Berggren; Per-Olof Berggren
Journal:  Curr Opin Lipidol       Date:  2017-02       Impact factor: 4.776

5.  A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Authors:  Sumeet A Khetarpal; Xuemei Zeng; John S Millar; Cecilia Vitali; Amritha Varshini Hanasoge Somasundara; Paolo Zanoni; James A Landro; Nicole Barucci; William J Zavadoski; Zhiyuan Sun; Hans de Haard; Ildikó V Toth; Gina M Peloso; Pradeep Natarajan; Marina Cuchel; Sissel Lund-Katz; Michael C Phillips; Alan R Tall; Sekar Kathiresan; Paul DaSilva-Jardine; Nathan A Yates; Daniel J Rader
Journal:  Nat Med       Date:  2017-08-21       Impact factor: 53.440

6.  Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes.

Authors:  Karin Åvall; Yusuf Ali; Ingo B Leibiger; Barbara Leibiger; Tilo Moede; Meike Paschen; Andrea Dicker; Elisabetta Daré; Martin Köhler; Erwin Ilegems; Midhat H Abdulreda; Mark Graham; Rosanne M Crooke; Vanessa S Y Tay; Essam Refai; Stefan K Nilsson; Stefan Jacob; Lars Selander; Per-Olof Berggren; Lisa Juntti-Berggren
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

Review 7.  Review: The role of insulin resistance in nonalcoholic fatty liver disease.

Authors:  Kristina M Utzschneider; Steven E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

8.  Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.

Authors:  Haizhao Yan; Manabu Niimi; Fumikazu Matsuhisa; Huanjin Zhou; Shuji Kitajima; Yajie Chen; Chuan Wang; Xiawen Yang; Jian Yao; Dongshan Yang; Jifeng Zhang; Masami Murakami; Katsuyuki Nakajima; Yao Wang; Enqi Liu; Jingyan Liang; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-08-06       Impact factor: 8.311

9.  N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.

Authors:  Veronica J Alexander; Shuting Xia; Eunju Hurh; Steven G Hughes; Louis O'Dea; Richard S Geary; Joseph L Witztum; Sotirios Tsimikas
Journal:  Eur Heart J       Date:  2019-09-01       Impact factor: 29.983

10.  High-fructose and high-fat diet-induced insulin resistance enhances atherosclerosis in Watanabe heritable hyperlipidemic rabbits.

Authors:  Bo Ning; Xiaoyan Wang; Ying Yu; Ahmed Bilal Waqar; Qi Yu; Tomonari Koike; Masashi Shiomi; Enqi Liu; Yifei Wang; Jianglin Fan
Journal:  Nutr Metab (Lond)       Date:  2015-08-12       Impact factor: 4.169
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.